Table 3.
Case characteristics and treatment costs by third-line interventions
| BSC | alloSCT | CAR T | ||
|---|---|---|---|---|
| tisa-cel | axi-cel | |||
| Patients no. (%) | 11 (17.74) | 14 (22.58) | 20 (32.26) | 17 (27.42) |
| Sex no. (%) | ||||
| Female | 3 (4.84) | 7 (11.29) | 12 (19.35) | 6 (9.68) |
| Male | 8 (12.90) | 7 (11.29) | 8 (12.90) | 11 (17.74) |
| Agea | 63 [32–83] | 49 [20–66] | 60 [23–82] | 62 [24–79] |
| Casemix index† | 6.97 [0.98–31.25] | 14.38 [10.56–16.98] | 1.70 [1.18–47.71] | 3.17 [1.59–29.52] |
| Length of stay in daysa | 52 [13–130] | 38 [23–51] | 21 [12–110] | 28 [19–111] |
| Number of side diagnosesa | 18 [5–47] | 19 [13–41] | 11.5 [2–51] | 21 [10–43] |
| Treatment costsa | € 26,918 [€ 0.00–€ 66,468] | € 73,829 [€ 61,337–€ 133,280] | € 310,496 [€ 294,113–€ 557,423] | € 340,458 [€ 316,272–€ 502,096] |
aMedian values [range]